1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998. 339:229–234.
2. American Diabetes Association. Standards of medical care in diabetes: 2010. Diabetes Care. 2010. 33:Suppl 1. S11–S61.
3. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Atherosclerosis Risk in Communities Study Investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003. 26:2777–2784.
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999. 340:115–126.
5. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004. 109:23 Suppl 1. III20–III26.
6. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001. 37:79–83.
7. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M. Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes. 2007. 56:2774–2779.
8. Kim EH, Yu JH, Lee SA, Kim EY, Kim WG, Lee SH, Cho EH, Koh EH, Lee WJ, Kim MS, Park JY, Lee KU. Lack of association between serum cystatin C levels and coronary artery disease in diabetic patients. Korean Diabetes J. 2010. 34:95–100.
9. Maahs DM, Snell-Bergeon JK, Hokanson JE, Kinney GL, Berl T, Rewers M, Ogden LG. Relationship between cystatin C and coronary artery atherosclerosis progression differs by type 1 diabetes. Diabetes Technol Ther. 2010. 12:25–33.